

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA HEALTH

China Health Technology Group Holding Company Limited

中國健康科技集團控股有限公司

(Incorporated in the Cayman Islands with limited liability and formerly known as

China Bozza Development Holdings Limited 中國寶沙發展控股有限公司)

(Stock code: 1069)

TRADING HALT, INSIDE INFORMATION AND RESUMPTION OF TRADING

At the request of China Health Technology Group Holding Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”), trading in the shares of the Company (the “**Shares**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) has been halted with effect from 9:00 a.m. on Monday, 13 July 2026 pending release of an inside information announcement pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company announces that on 10 July 2026, Ms. Bi Xue (“**Ms. Bi**”), the Chairman and Executive Director of the Company, reported to the Board that the Futian Branch of Shenzhen Municipal Public Security Bureau (the “**Futian PSB**”) had attended the Company’s place of business in Shenzhen, the People’s Republic of China (the “**PRC**”) and seized certain documents.

It was subsequently reported by Ms. Bi that (i) the above place was the office of Shanqingshuixiu Holdings (Shenzhen) Co., Ltd.* (山清水秀控股(深圳)有限公司) (“SQSX”), a subsidiary of the Company principally engaged in ginseng trading and the bank account of SQSX had been frozen by Futian PSB; and (ii) Ms. Cao Xiyang, a former executive director of the Company had been detained. All the above incidents are collectively referred to as the “**Alleged Incidents**”.

There are several operating subsidiaries of the Company in the PRC engaging in ginseng business. The total amounts in the SQSX’s bank account being frozen are less than HK\$1,000 and are not significant. The revenue of SQSX was approximately RMB4,853,000, representing approximately 5.4% of the Group’s total revenue, for the year ended 30 June 2025; and the business scale of SQSX has not been significant from 1 July 2025 to the date of this announcement. As such, SQSX is not considered as a major subsidiary of the Group’s ginseng business from this perspective.

The Company is currently conducting investigation on the Alleged Incidents and taking steps to further verify the veracity and details of the Alleged Incidents and to assess any potential impact to the business operations and financial condition of the Group’s ginseng business. Save as disclosed in this announcement, to the best of the knowledge, information and belief of the Board, the Alleged Incidents have no material adverse impact on the Group’s other business segments; and the Board considers that there is no other inside information that need to be brought to attention of the shareholders of the Company and the Stock Exchange.

THE RIGHTS ISSUE AND THE PLACING

References are made to (i) the announcements of the Company dated 27 March 2026 and 16 June 2026; (ii) the circular of the Company dated 24 April 2026; (iii) the poll results announcement of the Company dated 12 May 2026; and (iv) the prospectus of the Company dated 22 May 2026 (the “**Prospectus**”) in relation to, among other things, the Rights Issue and the Placing. Capitalised terms used herein shall have the same meanings as those defined in the Prospectus unless the context otherwise requires.

Despite the expected timetable of the Placing has not been met, as at the date of this announcement, the Placing Agreement remains valid and has not been terminated. The conditions precedent to the Placing Agreement have been fulfilled or waived (if applicable) and the Placing Agreement has become unconditional by the Long Stop Date. The Placing Agent has successfully identified placees to subscribe 146,928,745 Shares in aggregate, being the total number of the Unsubscribed Rights Shares, representing approximately 47.58% of the total number of Shares as at the date of this announcement as enlarged by the 146,928,745 Shares.

However, in view of the Alleged Incidents, the completion of the Placing has been delayed. The Company shall continue to proceed with the Placing and it is expected that the Placing shall be completed on or before 31 August 2026.

The Company will make further announcement(s) in relation to the Alleged Incidents, the Rights Issue and the Placing as and when appropriate in accordance with the Rules Governing the Listing of Securities on the Stock Exchange.

RESUMPTION OF TRADING

At the request of the Company, trading in the Shares was halted on the Stock Exchange with effect from 9:00 a.m. on Monday, 13 July 2026. Application has been made by the Company to the Stock Exchange for the resumption of trading in the Shares with effect from 9:00 a.m. on Thursday, 20 August 2026.

Shareholders of the Company and potential investors are advised to exercise caution in dealing in the shares of the Company.

By order of the Board
China Health Technology Group Holding Company Limited
Bi Xue
Chairman and Executive Director

Hong Kong, 19 August 2026

As at the date of this announcement, the Board comprises Ms. Bi Xue, Mr. Leung Ka Wai and Ms. Wong Hoi Ying as the executive Directors; and Mr. Chau Wing Nam, Ms. Liu Shuhua and Mr. Li Liangjie as the independent non-executive Directors.

** For identification purposes only*